biotech · Melanoma · Previously untreated, unresectable, or metastatic melanoma · IOBTQ
IO Biotech
IO Biotech is a biotech organization headquartered in copenhagen, DK. It trades on NYSE under ticker IOBTQ. Primary therapeutic focus areas include Melanoma, Previously untreated, unresectable, or metastatic melanoma, ad
Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK HQ
2015 Founded
50 Employees
Public company Type
IOBTQ · NYSE Ticker
Company details
- Status
- Public
- HQ
- Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK
- Founded
- 2015
- Employees
- 50
- Programs
- 16
- Drugs
- 8
- Patents
- 21
Pembrolizumab
Phase 2 · small molecule · Head and Neck Squamous Cell Carcinoma
Pembrolizumab for Head and Neck Squamous Cell Carcinoma is a Phase 2 program (small_molecule) at IO Biotech with 1 ClinicalTrials.gov record(s).
Internal code J22106
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- IO Biotech
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Head and Neck Squamous Cell Carcinoma
- Status
- active
- Trials
- 1